Real-world comparison of effectiveness between ustekinumab and a second-line anti-TNF agent in patients with symptomatic stricturing Crohn’s disease failing to respond to a first-line anti-TNF agent: the USTEKNOSIS study
Ustekinumab appears more effective than a second-line anti-TNF in patients with symptomatic stricturing CD after failing to respond to a first-line anti-TNF.
Authors
- Guillaume Le Cosquer (ORCID: https://orcid.org/0000-0001-8416-5432)
- Mathurin Fuméry (ORCID: https://orcid.org/0000-0002-2337-2902)
- Anthony Buisson (ORCID: https://orcid.org/0000-0002-6347-409X)
- Arthur Jammet
- Bruno Pereira
Institutions
- Université Toulouse III - Paul Sabatier (FR)
- Inserm (FR)
- Université Clermont Auvergne (FR)
- University of Clermont Auvergne (FR)
- Hôpital Rangueil (FR)
- Microbe, Intestine, Inflammation and Host Susceptibility (FR)
- Centre Hospitalier Universitaire de Clermont-Ferrand (FR)
- Clermont Université (FR)
- Périnatalité & Risques Toxiques (FR)
- Université de Picardie Jules Verne (FR)
Publication Details
- Journal
- Therapeutic Advances in Gastroenterology
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1177/17562848251389476
- Citations
- 1
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 1.82
Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- Biogen
- Celltrion
- Vifor Pharma
- Nordic Pharma Group
- Norgine